Leap Therapeutics (FRA:5MC) ROE % Adjusted to Book Value : -48.71% (As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Leap Therapeutics ROE % Adjusted to Book Value?

Leap Therapeutics's ROE % for the quarter that ended in Dec. 2024 was -151.97%. Leap Therapeutics's PB Ratio for the quarter that ended in Dec. 2024 was 3.12. Leap Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -48.71%.

Leap Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Leap Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Leap Therapeutics ROE % Adjusted to Book Value Chart

Leap Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-46.59

-22.00

-96.11

-68.81

-46.67

Leap Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-38.05	-72.55	-145.80	-61.95	-48.71

Competitive Comparison of Leap Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Leap Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Leap Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Leap Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Leap Therapeutics's ROE % Adjusted to Book Value falls into.

Save Embed

;

Save Embed

;

Leap Therapeutics ROE % Adjusted to Book Value Calculation

Leap Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-145.60%	/	3.12
	=	-46.67%

Leap Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-151.97%	/	3.12
	=	-48.71%

Leap Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Leap Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Leap Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Leap Therapeutics Inc (FRA:5MC) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

LPTX:USA 5MC:Germany

Address

47 Thorndike Street, Suite B1-1, Cambridge, MA, USA, 02141

Website

https://www.leaptx.com

Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .

Leap Therapeutics Headlines

No Headlines